Note 7 - Acquisition of EGEN, Inc. (Details) (USD $)	3 Months Ended		6 Months Ended					0 Months Ended				3 Months Ended	6 Months Ended		0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 06, 2014 Ovarian Cancer Study Milestone [Member] EGEN, Inc. [Member]	Jun. 06, 2014 Glioblastoma Multiforme Brain Cancer Study Milestone [Member] EGEN, Inc. [Member]	Jun. 06, 2014 TheraSilence Technology Milestone [Member] EGEN, Inc. [Member]	Jun. 06, 2014 In Process Research and Development [Member] EGEN, Inc. [Member]	Jun. 06, 2014 EGEN, Inc. [Member]	Jun. 06, 2014 EGEN, Inc. [Member]		Jun. 30, 2014 EGEN, Inc. [Member]	Jun. 30, 2014 EGEN, Inc. [Member]	Jun. 09, 2014 EGEN, Inc. [Member]	Jun. 06, 2014 EGEN, Inc. [Member] Maximum [Member]
Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred									$ 27,600,000	$ 27,578,000					$ 44,400,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					12,400,000	12,000,000	6,000,000					30,400,000	30,400,000
Payments to Acquire Businesses, Gross									3,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)									2,712,188	670,070
Shares Reserved for Contingent Consideration (in Shares)									670,070
Loans Payable														5,000,000
Business Combination, Consideration Transferred, Liabilities Incurred										13,878,000	[1]
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount									1,900,000	1,900,000
Goodwill, Acquired During Period									1,900,000
Business Combination, Acquisition Related Costs	1,067,267		1,067,267									1,067,267	1,067,267
Finite-lived Intangible Assets Acquired								25,800,000
Operating Expenses	$ 6,537,948	$ 3,973,296	$ 11,864,973	$ 8,865,202								$ 169,000	$ 169,000

[1] The difference between the aggregate $30.4 million in future Earnout Payments and the $13.9 million included in the fair value of the acquisition consideration was based on the Company's risk-adjusted assessment of each milestone and utililizing a discount rate based on the estimated time to achieve the milestone.